**To the Editor**: The New Delhi metallo-β-lactamase (NDM-1) was first characterized in 2009 from *Klebsiella pneumoniae* and *Escherichia coli* isolated from a patient in Sweden who had received medical care in New Delhi, India ([@R1]). Further studies have shown broad dissemination of this β-lactamase gene (*bla*~NDM-1~) in India, Pakistan, Bangladesh, and the United Kingdom ([@R2]). Additional isolates have been detected in other countries, and many of the patients with NDM-1--producing *Enterobacteriaceae* reported receiving medical care in the Indian subcontinent ([@R1]*--*[@R7]). We describe detection and characterization of an NDM-1--producing *K. pneumoniae* isolated in Ontario, Canada.

In August 2010, a urinary tract infection was diagnosed in a 36-year-old woman in a hospital in Brampton, Ontario. An *E. coli* strain sensitive to multiple antibacterial drugs (including carbapenems) was isolated from a midstream urine sample; the patient was successfully treated with ciprofloxacin. One week after treatment, when the patient did not have a fever or other clinical signs, a urine culture was repeated, and a carbapenem-resistant *K. pneumoniae* isolate (GN529) was recovered. Travel history indicated that the patient had recently returned from India, where in mid-July she had had a miscarriage and had been hospitalized in Mumbai for 2 days. At that time, no antimicrobial drug treatment was prescribed.

Susceptibility profiles of *K. pneumoniae* GN529 and its *E. coli* transconjugant were obtained by using Etest (bioMérieux, Marcy l'Etoile, France) and the agar dilution method based on the Clinical and Laboratory Standards Institute guidelines ([@R8]). Multilocus sequence typing (MLST) of isolate GN529 was performed as described ([@R9]). The Pasteur Institute online database ([www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html](http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html)) was used to assign the allelic numbers and sequence type (ST).

To screen for the most commonly known β-lactamase genes in enterobacteria, we performed multiplex PCRs ([@R10]). Primers were designed (NDM-F, 5′-AATGGAATTGCCCAATATTATGC-3′; NDM-R, 5′-CGAAAGTCAGGCTGTGTTG C-3′) for the specific detection of *bla*~NDM-1~ and included in 1 of the multiplex PCRs (multiplex V). Primers NDM-F and NDM-R2 (5′-TCAGCGCAGCTTGTCGGC-3′) were used to amplify and sequence the entire *bla*~NDM-1~ gene. The samples were screened for the presence of six 16S methylase genes (*armA*, *rmtA--D*, and *npmA*) by PCR. *E. coli* J53 transconjugants were selected on Luria-Bertani plates containing sodium azide and meropenem (100 µg/mL and 1 µg/mL, respectively). The plasmid harboring *bla*~NDM-1~ was identified by Southern blot analysis by using a specific digoxigenin-labeled *bla*~NDM-1~ probe (Roche Diagnostics, Indianapolis, IN, USA).

*K. pneumoniae* GN529 was highly resistant to all β-lactams, aminoglycosides, quinolones, tetracycline, nitrofurantoin, and co-trimoxazole. MICs of 0.5 µg/mL for colistin (European Committee on Antimicrobial Susceptibility Testing colistin breakpoint for *Enterobacteriaceae*: susceptibility [\<]{.ul}2 μg/mL) and 1 μg/mL for tigecycline (European Committee on Antimicrobial Susceptibility Testing and US Food and Drug Administration tigecycline breakpoint for *Enterobacteriaceae*: susceptibility [\<]{.ul}1 and [\<]{.ul}2 μg/mL, respectively) were also obtained ([Table](#T1){ref-type="table"}).

###### Antibacterial drug susceptibility profiles and resistance genes of *Klebsiella pneumoniae* GN529 clinical isolate and its *Escherichia coli* transconjugant, Ontario, Canada, 2010\*

  ---------------------------- -------------- -------------- -------
  Antibacterial drug or gene   MIC, μg/mL                    
  Kpn GN529                    Eco J529       Eco J53        
  Ampicillin                   [\>]{.ul}256   [\>]{.ul}256   6
  Cefoxitin                    [\>]{.ul}256   [\>]{.ul}256   8
  Ceftazidime                  [\>]{.ul}256   [\>]{.ul}256   0.19
  Cefotaxime                   [\>]{.ul}256   [\>]{.ul}256   0.094
  Cefepime                     48             48             0.064
  Ertapenem                    32             12             0.008
  Meropenem                    [\>]{.ul}32    4              0.023
  Imipenem                     [\>]{.ul}32    32             0.38
  Amikacin                     [\>]{.ul}256   [\>]{.ul}256   1.5
  Gentamicin                   [\>]{.ul}256   [\>]{.ul}256   1.5
  Tobramycin                   [\>]{.ul}256   [\>]{.ul}256   1
  Ciprofloxacin                [\>]{.ul}32    0.012          0.012
  Tetracycline                 [\>]{.ul}16    0.78           1
  Tigecycline                  1              ND             ND
  Nitrofurantoin               [\>]{.ul}512   ND             ND
  Colistin                     0.5            ND             ND
  Co-trimoxazole               4/76           ND             ND
  PCR† and sequencing                                        
  *bla*~NDM-1~                 \+             \+             ND
  *bla*~CTX-M-15~              \+             −              ND
  *bla*~SHV-12~                \+             \+             ND
  *bla*~SHV-11~                \+             --             ND
  *bla*~OXA-1~                 \+             --             ND
  *bla*~TEM-1~                 \+             --             ND
  *armA*                       \+             \+             ND
  ---------------------------- -------------- -------------- -------

\*Kpn, *Klebsiella pneumoniae*; Eco J529, *Escherichia coli* transconjugant strain; Eco J53, recipient *E. coli* J53; ND, not determined. †PCR screening included *bla*~TEM~, *bla*~SHV~, *bla*~OXA-1~-like, *bla*~CTX-M~ groups 1, 2, and 9, *bla*~VEB~, *bla*~PER~, *bla*~GES~, *bla*~OXA-48~-like, *bla*~IMP~, *bla*~VIM~, *bla*~KPC~, *bla*~NDM-1~, and 6 groups of *bla*~AmpC~ genes.

Considering the travel history of the patient and the high level resistance to all β-lactams, molecular screening of β-lactamases in strain GN529 was initiated to identify possible carbapenemases (e.g., *bla*~NDM-1~) in that isolate. Five β-lactamases genes (*bla*~NDM~, *bla*~SHV~, *bla*~TEM~, group 1 *bla*~CTX-M~ , and *bla*~OXA~) and one 16S rRNA methylase (*armA*) were detected. By using primers for amplification of complete genes, we obtained sequences of *bla*~NDM-1~, 2 extended-spectrum β-lactamases (*bla*~CTX-M-15~ and *bla*~SHV-12~), 3 broad-spectrum β-lactamases (*bla*~SHV-11~, *bla*~TEM-1~ and *bla*~OXA-1~), and methyltransferase *armA*. No AmpC β-lactamases were linked to this isolate. Southern blotting identified a plasmid of ≈150 kb harboring *bla*~NDM-1~ (data not shown). A transconjugant *E. coli* positive for *bla*~NDM-1~ (*E. coli* J529, Table) was resistant to all β-lactams and aminoglycosides tested. In addition, *bla*~SHV-12~ and *armA* were detected in strain J529 ([Table](#T1){ref-type="table"}), indicating the potential for the horizontal spread of these resistance genes.

*K. pneumoniae* GN529 was typed by MLST as ST147, the same type as a clinical NDM-1--producing strain isolated in Australia ([@R6]) but distinct from ST14 and ST16 strains described ([@R1]*,*[@R7]). There are insufficient MLST data to confirm polyclonal dissemination of NDM-1, but previous pulsed-field gel electrophoresis results support that hypothesis ([@R2]).

*K. pneumoniae* GN529 was isolated from a patient who had recently received emergency medical care in India, suggesting importation of this clinical strain. In the United Kingdom, where *Enterobacteriaceae* containing *bla*~NDM-1~ are increasingly common, carriage of these organisms has been closely linked to receipt of medical care in the Indian subcontinent ([@R2]). Similar association as a risk factor was observed in other regions, including *bla*~NDM-1~-positive clinical strains isolated in North America, Australia, and Africa ([@R3]*--*[@R6]*,*[@R10]).

The NDM-1--producing enterobacteria described in this study previously had low MICs only for colistin and tigecycline ([@R1]*,*[@R2]*,*[@R5]*,*[@R6]). However, an NDM-1 isolate resistant to these antimicrobial drugs has also been described ([@R2]). Early detection and implementation of infection control interventions is essential for preventing the spread of multidrug-resistant organisms such as these. It may be prudent to consider medical exposure in the Indian subcontinent as a risk factor for possible infection, colonization, or both with multidrug-resistant, NDM-1--producing *Enterobacteriaceae*.
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